This is the second in a five-part BioPharma Blog Series.
In the ever-evolving field of biopharmaceuticals, where scientists and researchers strive to develop life changing therapies, an unsung hero resides within the intricate landscape – column chemistries. The significance of column chemistry in biopharmaceutical development cannot be overstated. As a cornerstone technique in bio separations, chromatography plays a pivotal role in characterization and analysis of biopharmaceutical products. It is no surprise that innovation in this field sparks excitement.
We are thrilled to share with our readers the latest advancements in this arena. At a recent conference, Thermo Fisher Scientific presented a series of posters, four of which specifically highlighted the value of using our most innovative columns in typical biopharmaceutical applications such as peptide mapping, native intact mass analysis, and characterization. Additionally, our esteemed collaborators at the National Institute for Bioprocessing and Training (NIBRT) presented a poster detailing their experience with the Thermo Scientific monodisperse strong cation exchange (SCX) columns in characterizing the originator and seven biosimilars of the monoclonal antibody adalimumab.
Our Biopharma applications team also showcased their work on peptide mapping and the adoption of low flow chromatography in this field. The scientists conducted tests using our µPac Neo HPLC columns and demonstrated that when peptide mapping is performed using the 50 cm µPAC Neo and 5.5 cm High Throughput µPAC Neo columns, outstanding results are achieved. Using only 20ng of NISTmAb tryptic digest, they attained 96.4% and 98.6% coverage for the heavy chain (HC) and light chain (LC), respectively, in just 15 minutes of elution time with the 50 cm µPAC Neo column. The same sequence coverages were achieved in a mere 5 minutes of elution time using the 5.5 cm High Throughput µPAC Neo column.
We have made available the detailed posters for download, which highlight the following:
- The use of a newly developed online buffer exchange (OBE) column coupled with native mass spectrometry (nMS) to support the development of new protein drugs and process optimization.
- A 2 × 50 mm, 3 μm monodisperse SCX column employed for online SCX-MS charge variant analysis of durvalumab using an MS compatible salt buffer system.
- The utilization of the monodisperse strong cation exchange (SCX) column and its advantages in characterizing the originator and seven biosimilars of the monoclonal antibody adalimumab.
- A 5.5 cm High Throughput µPAC Neo column, which provides the same sequence coverage as its 50 cm equivalent in peptide mapping.
Don’t miss the opportunity to access this valuable information and discover how you can enhance your biopharmaceutical analysis today.
Related information
Blog 1: Revolutionizing Host Cell Protein Detection and mAb Analysis in Biopharmaceuticals
Blog 3: Take a Step Closer to Unlocking Full Potential of AAV Gene Therapy – Download the Poster
Blog 4: Unlocking the Future of Medicine: Exploring Therapeutic Oligonucleotides
Blog 5: Unveiling Hidden Impurities: LC-HRMS for Biopharmaceutical Analysis
Download our conference posters to see how we applied advanced analytical technology to achieve the best results for oligonucleotide analysis
On LinkedIn? Visit our LinkedIn page #biopharmaceutical